TIC10
CAS No. 1616632-77-9
TIC10 ( ONC-201 )
产品货号. M18091 CAS No. 1616632-77-9
TIC10 灭活 Akt 和 ERK,通过 Foxo3a 诱导 TRAIL,具有卓越的化合物特性:穿过血脑屏障的递送、卓越的稳定性和改进的药代动力学。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥473 | 有现货 |
|
| 10MG | ¥685 | 有现货 |
|
| 25MG | ¥1237 | 有现货 |
|
| 50MG | ¥2158 | 有现货 |
|
| 100MG | ¥3222 | 有现货 |
|
| 200MG | ¥4878 | 有现货 |
|
| 500MG | ¥7542 | 有现货 |
|
| 1G | ¥10080 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥504 | 有现货 |
|
生物学信息
-
产品名称TIC10
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述TIC10 灭活 Akt 和 ERK,通过 Foxo3a 诱导 TRAIL,具有卓越的化合物特性:穿过血脑屏障的递送、卓越的稳定性和改进的药代动力学。
-
产品描述TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.(In Vitro):Dordaviprone transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier.Dordaviprone induces a sustained up-regulation of TRAIL in tumors and normal cells that may contribute to the demonstrable antitumor activity of Dordaviprone.Dordaviprone inactivates kinases Akt and extracellular signal-regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription.Dordaviprone is an efficacious antitumor therapeutic agent that acts on tumor cells and their micro-environment to enhance the concentrations of the endogenous tumor suppressor TRAIL.Dordaviprone also causes a down-regulation of the total expression of ERK. (In Vivo):In DLD-1 colon cancer xenografts, Dordaviprone induces tumor stasis at 1 week after treatment, whereas TRAIL-treated tumors progress after a single dose. A single dose of Dordaviprone also induces a sustained regression of the SW480 xenograft and is equally effective when delivered by intraperitoneal or oral route, suggesting favorable oral bioavailability for Dordaviprone. Titration of a single oral dose of Dordaviprone in the HCT116 xenograft model reveals sustained antitumor efficacy at 25 mg/kg. Exposure to oral Dordaviprone at 25 mg/kg weekly for 4 weeks in immunocompetent mice does not cause any changes in selected serum chemistry markers. The same oral dosing schedule is applied to Eμ-myc transgenic mice, which spontaneously develop meta-static lymphoma from weeks 9 to 12 of age, and Dordaviprone significantly (P=0.00789) prolongs the survival of these mice by 4 weeks.
-
体外实验——
-
体内实验——
-
同义词ONC-201
-
通路Others
-
靶点Other Targets
-
受体TRAIL
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1616632-77-9
-
分子量386.49
-
分子式C24H26N4O
-
纯度>98% (HPLC)
-
溶解度DMSO : 33.33 mg/mL 86.24 mM
-
SMILESCC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Mal-amido-PEG7-acid
Mal-amido-PEG7-acid 是一种基于 PEG 的 PROTAC 连接子,可用于合成 PROTAC。
-
[D-Arg0,Hyp3,D-Phe7,...
[D-Arg0,Hyp3,D-Phe7,Leu8]-Bradykinin
-
Nrf2 activator-4
Nrf2 activator-4 (Compound 20a) 是一种高效的、具有口服活性的 Nrf2 激活剂,EC50 值为 0.63 μM。Nrf2 activator-4 抑制小神经胶质细胞中活性氧 (reactive oxygen species) 的产生。Nrf2 activator-4 在 scopolamine 诱导的小鼠模型中能有效地恢复学习和记忆损伤。
021-51111890
购物车()
sales@molnova.cn

